AstraZeneca PLC (AZN.L)

Mon, Sep 24 2018

EU approves AstraZeneca immunotherapy drug for lung cancer

LONDON AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.

EU approves AstraZeneca immunotherapy drug for lung cancer

LONDON, Sept 24 AstraZeneca's immunotherapy drug Imfinzi has been approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body, the drugmaker said on Monday.

AstraZeneca diabetes drug cuts heart risks in major study

LONDON AstraZeneca's diabetes drug Farxiga met a key goal in a major clinical study designed to show its heart-protecting benefits in a wide range of patients, potentially distinguishing it from rivals in a crowded marketplace.

UPDATE 1-AstraZeneca diabetes drug cuts heart risks in major study

* Farxiga cuts hospitalisation for heart failure and CV death

AstraZeneca diabetes drug cuts heart risks in major study

LONDON, Sept 24 AstraZeneca said on Monday its diabetes drug Farxiga met a key goal in a major clinical study designed to show the heart-protecting benefits of the medicine.

AstraZeneca CEO warns of medicine shortages after Brexit: Sunday Times

LONDON Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times.

AstraZeneca ceo warns of medicine shortages after Brexit - Sunday Times

LONDON, Sept 22 Britain could see widespread medicine shortages if there is no deal to prevent friction at the border with the European Union after Brexit, the AstraZeneca chief executive told the Sunday Times.

RPT-FOCUS-AstraZeneca plots China robot offensive to counter price cuts

* AstraZeneca out-grows rivals in world's no. 2 pharma market

AstraZeneca plots China robot offensive to counter price cuts

WUXI, China/LONDON With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

Select another date: